University of Massachusetts Medical School Faculty Publications

Title

No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia

UMMS Affiliation

Department of Psychiatry

Date

4-2013

Document Type

Article

Medical Subject Headings

Schizophrenia; Insulin; Cognition; Psychopathology

Disciplines

Mental and Social Health | Mental Disorders | Psychiatry and Psychology | Therapeutics

Abstract

OBJECTIVE: This study examined the effect of adjunctive intranasal insulin therapy on psychopathology and cognition in patients with schizophrenia.

METHODS: Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder and been on stable antipsychotics for at least 1 month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale and the Scale for Assessment of Negative Symptoms. A neuropsychological battery was used to assess cognitive performance. The assessment for psychopathology and cognition was conducted at baseline, week 4, and week 8.

RESULTS: A total of 45 subjects were enrolled in the study (21 in the insulin group and 24 in the placebo group). The mixed model analysis showed that there were no significant differences between the 2 groups at week 8 on various psychopathology and cognitive measures (P > 0.1).

CONCLUSIONS: Adjunctive therapy with intranasal insulin did not seem to be beneficial in improving schizophrenia symptoms or cognition in the present study. The implications for future studies were discussed.

Rights and Permissions

Citation: J Clin Psychopharmacol. 2013 Apr;33(2):226-30. doi: 10.1097/JCP.0b013e31828701d0. Link to article on publisher's site

Related Resources

Link to Article in PubMed

PubMed ID

23422397